22 February 2013 Effects of interstitial laser immunotherapy for the treatment of metastatic cancer
Author Affiliations +
Proceedings Volume 8582, Biophotonics and Immune Responses VIII; 858207 (2013) https://doi.org/10.1117/12.2006462
Event: SPIE BiOS, 2013, San Francisco, California, United States
Laser immunotherapy (LIT) uses laser irradiation and immunological stimulation to treat metastatic cancers. The current mode of operation of LIT is through dye-enhanced non-invasive irradiation. Although this treatment has given promising results, there are still a number of challenges with this method, such as limited light penetration for deep tumors and strong light absorption by highly pigmented skins. Interstitial laser immunotherapy (ILIT), using a cylindrical diffuser, is designed to overcome these limitations. In this study, rat tumors were treated by ILIT with an 805 nm laser and varying doses of glycated chitosan, an immunological stimulant. The goal was to observe the effects of differing doses of the stimulant on the survival of the tumor-bearing rats. The results suggested that the optimal dose of glycated chitosan is in the range of 0.1 to 0.3 ml per rat tumor.
© (2013) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Cody Bahavar, Cody Bahavar, Jessica Goddard, Jessica Goddard, Allie Sikes, Allie Sikes, Ellen Boarman, Ellen Boarman, Robert E Nordquist, Robert E Nordquist, Tomas Hode, Tomas Hode, Hong Liu, Hong Liu, Wei R. Chen, Wei R. Chen, "Effects of interstitial laser immunotherapy for the treatment of metastatic cancer", Proc. SPIE 8582, Biophotonics and Immune Responses VIII, 858207 (22 February 2013); doi: 10.1117/12.2006462; https://doi.org/10.1117/12.2006462

Back to Top